NGS Group Valuation

Is NGS undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of NGS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate NGS's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate NGS's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for NGS?

Key metric: As NGS is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for NGS. This is calculated by dividing NGS's market cap by their current revenue.
What is NGS's PS Ratio?
PS Ratio	0.2x
Sales	SEK 387.41m
Market Cap	SEK 77.42m

NGS key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	0.2x
Enterprise Value/EBITDA	-1x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does NGS's PS Ratio compare to its peers?

The above table shows the PS ratio for NGS vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	1.3x
HEGR Hedera Group	0.06x	n/a	SEK 36.1m
L2S Learning 2 Sleep L2S	3.7x	n/a	SEK 10.6m
DEDI Dedicare	0.3x	n/a	SEK 592.9m
ORTI B Ortivus	1x	n/a	SEK 81.5m
NGS NGS Group	0.2x	n/a	SEK 77.4m

Price-To-Sales vs Peers: NGS is good value based on its Price-To-Sales Ratio (0.2x) compared to the peer average (1.3x).

Price to Sales Ratio vs Industry

How does NGS's PS Ratio compare vs other companies in the European Healthcare Industry?

7 Companies	Price / Sales	Estimated Growth	Market Cap

7 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: NGS is good value based on its Price-To-Sales Ratio (0.2x) compared to the European Healthcare industry average (0.6x).

Price to Sales Ratio vs Fair Ratio

What is NGS's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

NGS PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	0.2x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate NGS's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Dignitana

SEK 95.8m

A medical technology company, engages in the development, production, and marketing of medical cooling devices in the United States and internationally.

DIGN

SEK 1.19

3.5%

-45.9%

Arcoma

SEK 146.4m

Develops, produces, and provides radiology solutions worldwide.

ARCOMA

SEK 11.10

2.8%

49.0%

Iconovo

SEK 80.5m

Develops and licenses inhalation medications in Sweden.

ICO

SEK 5.06

2.4%

-45.1%